Tandem Diabetes Care (TNDM) Q3 2026 earnings review
Tandem's sales rose 14%, but it now expects slower growth
Insulin-pump maker Tandem Diabetes Care sold more than planned, but patients are adopting its new payment model slowly. Sales rose 14%, about 7% above the company's plan for the quarter. Yet finance chief Leigh Vosseller kept the full-year outlook, so by our math the fourth quarter shows almost no growth.
| Sales | $283.7M +14% from a year ago; plan was about $265M |
|---|---|
| Gross margin | 57% 54% a year ago |
| Pharmacy share of US sales | 15% 10% last quarter |
| Full-year sales outlook | Unchanged $1.065–1.085B; Q4 about flat by our math |
⚖️ Verdict: 🔴 Bearish
The story got worse, because patients are moving to pharmacy billing more slowly than Tandem hoped. Under that model the pump ships free, and Vosseller expects the resulting hit to sales to last into 2027. The good news: gross margin widened by about 3 percentage points, and new US patients returned to growth.
The question now is whether pharmacy billing spreads fast enough to end that hit next year. Tandem bets that Mobi Tubeless, a pump without tubing sold only through pharmacies, will speed the switch; a late launch would stretch the hit. The fourth-quarter pharmacy share of pumps, due with the year-end results, will tell first.
🐂 Bull Case
Higher Prices Lifted Profit Margins
Gross margin, the share of sales left after the cost of making the products, reached 57% in the third quarter, against 54% a year earlier. Tandem credited "favorable pricing from the increase in U.S. pharmacy sales and direct international sales".
Pharmacy patients get the pump free and pay more each month for supplies. Finance chief Leigh Vosseller said that monthly price is "averaging closer to $400 right now", above the $350 the insulin-pump maker had planned on. She added: "Our supply margins hit a record high".
- Cost of making the products: down 2.7 percentage points of sales
- Sales and administrative costs: down 3.3 percentage points of sales
- Research spending: down 2.3 percentage points of sales
- Operating margin: minus 1%, against minus 9% a year ago
This matters because higher supply prices lift profit without needing more patients. Stock pay also fell by $5 million, so part of the saving does not come from a leaner business.
What to watch: fourth-quarter gross margin, reported with the year-end results, against the target Tandem has set. Holding the gain would show that pharmacy pricing survives as more patients switch.
Sales Abroad Hit a Record
Outside the US, Tandem is replacing local distributors with its own sales teams, so it keeps the margin the middlemen used to take. Direct selling started this year in Britain, Switzerland and Austria, and chief executive John Sheridan said France follows this week.
International sales rose 26%, the best quarter in Tandem's history. Direct sales made up 18% of the total, against 3% a year ago. Part of the gain will not repeat, because the quarter included supply orders that slipped from the second quarter, finance chief Leigh Vosseller said.
What to watch: the direct share of international sales once France joins in the fourth quarter. A rising share would show the higher direct prices spreading beyond the first three countries.
More New Patients Started on Tandem Pumps
New patient starts, people buying their first Tandem pump rather than replacing an old one, weakened through 2025 and were roughly flat last quarter. Finance chief Leigh Vosseller said "This quarter, we did return to growth", though she gave no figure for the increase.
Most new users switch from daily insulin injections, and Vosseller said that group "grew nearly 10%". She credited Tandem Mobi, the company's smaller pump. US pump shipments, which include renewals, rose 11% from a year ago.
What to watch: US pump shipments in the fourth quarter, measured against a record 27,000 a year ago. Growth there would show that new demand, not only higher pharmacy prices, drives sales.
🐻 Bear Case
Patients Are Switching to Pharmacy Billing More Slowly
Tandem is moving US patients from the medical-equipment benefit, which paid about $4,000 upfront for a pump, to pharmacy billing. Under this pay-as-you-go model the pump is free, and Tandem earns more from monthly supplies. Chief executive John Sheridan said the quarter "demonstrates that our strategy is delivering results".
Pharmacies handled 15% of US sales, against 10% last quarter. But finance chief Leigh Vosseller said the pace is "more gradual than we initially anticipated". Tandem is "not going to reach those original assumptions that we put out there at the beginning of the year", she said. She now puts this year's pharmacy share of pumps at 10% to 12%. The original target was 20%.
The slower switch hurts sales, because each pharmacy pump ships free while the supply revenue that repays it builds only gradually. Vosseller said "we anticipate continued sales headwinds extending into 2027". She called mid- to high-single-digit growth next year "a really fair starting point".
What to watch: the share of pumps shipped through pharmacies in the fourth quarter, which Tandem plans at 15% to 20%. Reaching that range would show adoption gaining speed before 2027 begins.
Full Tubeless Mobi Launch Moves to 2027
Mobi Tubeless is an add-on that lets Tandem's Mobi pump stick to the body without tubing. Chief executive John Sheridan called it "the world's first and only tubeless AID system offering up to 7 days of wear", AID meaning automated insulin delivery. Finance chief Leigh Vosseller expects the pharmacy-only product to speed adoption of pharmacy billing.
Timing matters because a rival tubeless pump already competes for the same patients. The Food and Drug Administration has not cleared Mobi Tubeless yet. Last quarter, Sheridan aimed for a scaled launch this year. Now Tandem plans "limited customer use and then expand to full commercial availability in the first half of 2027".
What to watch: the FDA decision, which Sheridan expects in the fourth quarter. Clearance on that timetable would let the first patients start before the wider launch next year.
Cash Flow Turned Negative as Receivables Climbed
Free cash flow, the cash left after running the business and buying equipment, was minus $5.5 million, against plus $4.2 million a year ago. Tandem has used $39 million this way over nine months.
- Money owed by customers: $180 million, up 43% from a year ago
- Days needed to collect a sale: about 58, against 46 a year ago, by our math
- Loss from its minority stake in CeQur: $6.7 million, against $2.7 million
Finance chief Leigh Vosseller pointed to "continued investment to rebuild infusion set inventory to our desired stocking levels". But receivables grew three times as fast as sales, so slower collection also used cash.
What to watch: days needed to collect a sale in the fourth quarter. A further rise would mean more of Tandem's sales sit as unpaid bills.
Risks this quarter didn't answer
Five standing risks got partial readings at best this quarter. Each item below names the reading that would move it; none moved enough yet to change the case.
- Pharmacy prices: finance chief Leigh Vosseller cited supply revenue near $400 a month, but Tandem discloses no rebates; a net price would settle it.
- Infusion-set shortage: chief executive John Sheridan said "some level of impact remain into early 2027"; first-quarter supply sales will show it.
- Type 2 patients on Medicare: Sheridan said "C-peptide is a real problem", meaning a coverage requirement; a Medicare decision would move it.
- Year-end profit: the full-year margin plan rests on the fourth quarter; the year-end results will show whether it arrives.
- Execution: pharmacy billing, direct sales abroad and a launch pass to a new chief executive; her first annual plan will show it.
👓 Other Themes
Chief Executive Sheridan Retires at Year-End
John Sheridan, chief executive for eight years, retires at the end of 2026. Jeannette Bankes, who has led several medical-technology companies, joins Tandem on November 16 and succeeds him. Board chair Beckie Robertson said "Jeannette is the right leader to guide Tandem through its next phase of growth".
Currency Moves Barely Affected Sales
Exchange rates trimmed one percentage point from international growth, so sales abroad rose 27% at constant currency, the company said. Total sales growth stayed the same with or without currency effects. Tandem hedges part of its foreign revenue and costs with forward contracts covering $135 million of future transactions.
💲 Other KPIs
Inventory rose 4% from a year ago, far less than sales, as Tandem rebuilt stocks of infusion sets, the tubes that link pump and body. Days of stock on hand eased to about 107 from 112 in June, by our math, after a supplier shortage.
Net debt, convertible bonds minus cash and investments, edged up to $173 million from $160 million in June, by our math. The big step came in February, when the diabetes-device maker sold zero-interest bonds due 2032. Cash and investments stood at $443 million.
The share count rose 3% from a year ago, a pace unchanged for three quarters, because Tandem pays staff partly in stock and buys none back. Another 17 million shares could follow if bondholders convert their notes into stock.
🔮 Guidance
Unchanged. The plan still calls for about 6% growth this year. By our math, that leaves about $290 million for the fourth quarter, roughly level with a year ago. The same range pointed to about $308 million three months ago, so the third-quarter beat did not carry forward. Vosseller said she wanted room in case faster pharmacy adoption cuts sales.
Unchanged. The plan points to about 4% US growth this year. By our math, that leaves about $206 million for the fourth quarter, 2% below a year ago. More pumps shipping through pharmacies with no upfront charge explain the dip, against a record quarter last year.
Unchanged. The plan means about 10% growth abroad this year. By our math, that leaves about $83 million for the fourth quarter, 4% above a year ago and far below the third quarter's pace. The range also absorbs a $15 million hit from taking distribution back from local partners.
Unchanged. Tandem still expects gross margin to reach about 60% in the fourth quarter. By our math, the middle of the yearly range needs only about 57% in that quarter. A 60% finish would put the year near the top of the range.
Unchanged. Adjusted EBITDA is operating profit before interest, taxes, depreciation and stock pay. By our math, the middle of the range leaves about $32 million for the fourth quarter. That equals about 11% of sales, close to a year ago. The third quarter reached 6%, well above plan.
Unchanged. The total includes about $65 million of stock pay and $20 million of depreciation. By our math, about $24 million remains for the fourth quarter. Tandem lowered the stock-pay estimate from $80 million three months ago.
Unchanged. The plan still points to double-digit growth in US pumps this year. By our math, the fourth quarter needs about 30,500, roughly 13% above a year ago. That asks for a faster pace than the third quarter delivered.
❓ Key Questions
How fast will existing patients buy supplies through pharmacies?
Only about 7% of the installed base bought supplies through pharmacies in the third quarter. Those monthly orders repay the free pumps, so their pace decides when the hit to sales ends.
What net price does Tandem keep after pharmacy rebates?
Vosseller cited supply revenue near $400 a month but gave no rebate figure. Pharmacy benefit managers negotiate rebates, and the net price decides whether the margin gain lasts.
Why are customers taking longer to pay?
Collection time has risen for a year by our math. Tandem has not said whether pharmacy billing, direct sales abroad or slower insurers caused it.
When can every patient get Mobi Tubeless, and where?
The first filing covers wear on the abdomen only, and full availability waits until the first half of 2027. A firm date and approval for other body sites decide how fast pharmacy adoption picks up.
What return does Tandem expect from CeQur?
Tandem put $81 million more into CeQur in May and holds an option to buy the rest from 2028. Its share of CeQur's losses keeps rising, and it has given no return target.